Where Progress Lives: This Month in California Life Sciences August 2026

Each month, California Life Sciences (CLS) President and CEO Mike Guerra shares what’s shaping the life sciences industry, highlights the conversations that matter most to members, and offers a window into what the CLS team is working on.

Last month, I wrote about how the science moving out of California is the strongest argument there is for protecting the ecosystem that makes it possible. August built directly on that idea, and then some. Five CLS member companies won FDA approval this month, several of them delivering the first treatment of its kind for the disease it addresses, while five more advanced through Fast Track designation. We brought congressional staffers to see our ecosystem firsthand, and some of the biggest names in life sciences and technology struck partnerships that show just how much collaborative energy continues to define this moment for our industry.

A Month Defined By Firsts

On August 26, the FDA approved Revolution Medicines’ RASONQUE™ (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic adenocarcinoma – one of oncology’s hardest diagnoses. RAS is a protein researchers spent decades calling “undruggable,” and in the Phase 3 RASolute 302 trial, the once-daily oral therapy nearly doubled median overall survival compared with existing treatments while cutting the risk of death by a staggering 60%. Those results made headlines across the country when they were presented at the ASCO Annual Meeting in June, and received an almost minute-long standing ovation from those in attendance. Watching a company built right here in California establish a new standard of care for one of the most difficult diagnoses is exactly the kind of progress this ecosystem exists to produce.

Revolution Medicines wasn’t alone. Four more CLS member companies won FDA approvals in August, and a striking number of them were firsts. On August 5, Takeda received approval for ORZEYFUL™, the first medicine designed to treat the underlying cause of narcolepsy type 1 rather than its individual symptoms. On August 19, Ultragenyx won accelerated approval for GENGLYCOS™, a gene therapy and first-ever FDA-approved treatment designed to address the underlying cause of glycogen storage disease type Ia, an ultra-rare and life-threatening metabolic disorder. On August 25, BeOne Medicines won approval for a TEVIMBRA-based regimen as a first-line treatment for HER2-positive gastric, gastroesophageal junction, and esophageal cancer, becoming the first immunotherapy-based regimen to deliver more than two years of median survival in a disease that has historically been difficult to treat. And on August 27, Gilead won approval for Bixlenvo™, the smallest once-daily single-tablet regimen available for HIV and the first option for virologically suppressed patients on complex regimens who couldn’t take existing single-tablet therapies.

Five member companies won FDA approval in a single month, each for a different disease, and several of them among the hardest to treat in medicine. That kind of concentrated breakthrough doesn’t happen by accident. It reflects the depth and breadth of expertise built into this ecosystem, and it’s exactly the kind of innovation with the power to change the course of human health.

The Pipeline Behind Them

Approvals are the finish line, but California continues to be the place where the industry’s most promising science clears its earliest regulatory hurdles. In August, five companies headquartered in our state earned FDA Fast Track designation, a status designed to speed up the development and review of medicines poised to treat serious conditions and address unmet medical need.

Erasca received FDA Fast Track designation for ERAS-0015, an investigational treatment for metastatic pancreatic adenocarcinoma with a potential best-in-class profile. ADARx earned Fast Track designation for onvuzosiran, a treatment for a rare genetic disorder that also holds Orphan Drug designation. BlossomHill Therapeutics received Fast Track designation for BH-30643, an investigational treatment for advanced or metastatic non-small cell lung cancer. Pliant Therapeutics received Fast Track designation for PLN-101095, aimed at solid tumors that have grown resistant to immune checkpoint inhibitors. And CytomX received Fast Track designation for Varseta-M, a potential first-in-class antibody drug conjugate treatment for patients with relapsed/refractory metastatic colorectal cancer.

The FDA grants Fast Track designation sparingly, to roughly 200 therapies a year across the entire agency, an average of about 16 a month. Five of those designations landing with CLS member companies in a single month, every one of them headquartered here in California, says a great deal about where this kind of innovation is happening and who is leading it.

Bringing Washington to the Bay Area

California’s life sciences ecosystem was on full display as we joined Center Forward and congressional staff for a week of events exploring healthcare innovation from the lab to the clinic. Our visits reinforced why American leadership in biopharmaceutical innovation matters — not just for advancing science, but for the patients and families counting on new breakthroughs — and shed light on the people, policy, and partnerships driving the future of healthcare.

We’re grateful to Center Forward, Gilead, Stanford, SAMCEDA, Genentech, Biogen, UCSF Benioff Children’s Hospital, Merck, and the City of San Francisco for a firsthand look at how Congress can support the innovators tackling persistent and emerging public health threats and the research shaping the future of cancer and neurological disease treatment. Read the full recap of our week with California’s life sciences leaders here.

Collaboration as California’s Edge

California’s advantage shows up not only in the therapies advancing through the FDA, but in the collaborations forming around them. This month, Abbott and Google announced a partnership aimed at transforming everyday health through glucose insights and artificial intelligence. Novo Nordisk and AWS entered a strategic partnership to accelerate drug discovery using AI. And BeOne Medicines and Revolution Medicines announced a collaboration spanning clinical development and regional commercialization.

These key players in our sector continue to maintain a significant presence in California, drawn by the same research talent, infrastructure, and scientific community that make our state the place where this kind of partnership takes place. What connects all three deals is a growing recognition that the biggest problems in human health are best solved together, and that artificial intelligence in particular continues to expand what our researchers believe is possible.

Looking Ahead

August was a month that showed progress taking a lot of different forms: regulatory milestones for the companies building the next generation of therapies, advocacy that gave national policymakers a firsthand look at what California’s ecosystem looks like on the ground, and partnerships that prove our ecosystem’s advantage isn’t only about where a company’s headquarters sits, but about the community of talent, infrastructure, and ambition that keeps drawing this work here.

I am grateful for the colleagues and partners who make all of this possible, and I look forward to sharing more next month.

Mike Guerra is President and CEO of California Life Sciences (CLS), California’s most influential life sciences trade association, representing more than 1,300 member companies. He chairs the Council of State Bioscience Associations and sits on multiple industry boards, working to advance California’s position as the world’s leading life sciences innovation ecosystem. Mike champions effective public policy at the national, state, and local levels, and is a steadfast advocate for the entrepreneurs and businesses driving life sciences forward in California.